Clinical Trial Update: NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluates NBTXR3 hafnium oxide nanoparticles in combination with radiation therapy for inoperable recurrent non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NBTXR3 (hafnium oxide nanoparticles)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING